Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

1,432 questions · 1,467 findings · 116 reviews · Headline outcomes only

No studies found 232 · 15.8%GRADE not reported 202 · 13.8%Very low 286 · 19.5%Low 327 · 22.3%Moderate 286 · 19.5%High 134 · 9.1%

NSAIDs vs combination (paracetamol and opioid) analgesic

Return to function on day 7 or later Assessed as 'cure' · people with acute soft tissue injury, such as ankle sprain

It is very uncertain whether NSAID changes return to function on day 7 or later Assessed as 'cure' compared with combination (paracetamol and opioid) analgesic (very low certainty).

1 finding from 1 review

NSAIDs vs combination (paracetamol and opioid) analgesic

Gastrointestinal adverse events · people with acute soft tissue injury, such as ankle sprain

It is very uncertain whether NSAID changes gastrointestinal adverse events compared with combination (paracetamol and opioid) analgesic (very low certainty).

1 finding from 1 review

NSAIDs vs combination (paracetamol and opioid) analgesic

Neurological adverse effects · people with acute soft tissue injury, such as ankle sprain

It is very uncertain whether NSAID changes neurological adverse events compared with combination (paracetamol and opioid) analgesic (very low certainty).

1 finding from 1 review

Sunitinib vs adjuvant immunotherapy (combined ipilimumab and nivolumab)

Progression‐free survival (PSF) · Treatment‐naïve metastatic renal cell carcinoma (clear cell type); IMDC intermediate, poor risk patients only.

Sunitinib may leads to higher progression‐free survival (absolute effect size estimates based on… compared with nivolumab + ipilimumab (targeted agent versus combinations of… (low certainty).

1 finding from 1 review

Sunitinib vs adjuvant immunotherapy (combined ipilimumab and nivolumab)

Overall survival (absolute effect size estimates based on survival rate at 12 months) · Treatment‐naïve metastatic renal cell carcinoma (clear cell type); IMDC intermediate, poor risk patients only.

Sunitinib leads to higher overall survival (absolute effect size estimates based on survival… compared with nivolumab + ipilimumab (targeted agent versus combinations of… (high certainty).

1 finding from 1 review

Sunitinib vs adjuvant immunotherapy (combined ipilimumab and nivolumab)

Serious adverse events (Grade 3 or 4) · Treatment‐naïve metastatic renal cell carcinoma (clear cell type); IMDC intermediate, poor risk patients only.

Sunitinib probably leads to higher serious adverse events (Grade 3 or 4) compared with nivolumab + ipilimumab (targeted agent versus combinations of… (moderate certainty).

1 finding from 1 review

Intervention not reported

Total studies: 282 RCTs Total participants: 50,812 Number of treatments: 65 Geometry of the network** · adults undergoing any type of surgery under general anaesthesia Interventions: antiemetic drugs (monoprophylaxis and combination…
1 finding from 1 review